Debiopharm commences treatment in Phase I clinical trial for Debio 0932 small molecule Hsp90 inhibitor

Curis, Inc. (NASDAQ: CRIS) announced today that its licensee Debiopharm S.A. ("Debiopharm") has treated the first patient in a Phase I clinical trial for small molecule heat shock protein 90 (Hsp90) inhibitor Debio 0932, formerly called CUDC-305.

“We continue to be impressed by the performance of our partner Debiopharm in advancing Debio 0932 rapidly into Phase I clinical testing”

"We continue to be impressed by the performance of our partner Debiopharm in advancing Debio 0932 rapidly into Phase I clinical testing," said Dan Passeri, Curis' President and Chief Executive. "We look forward to the continued enrollment of this trial and the further exploration of the safety and tolerability of Debio 0932 in patients."

Under the terms of the August 2009 license agreement between Curis and Debiopharm, Curis will receive a $3 million milestone payment from Debiopharm upon Debiopharm's treatment of the fifth patient in this Phase I clinical trial.

Source Curis, Inc.